Advertisement

International Journal of Clinical Pharmacy

, Volume 41, Issue 1, pp 9–12 | Cite as

Clinical experience with the etanercept biosimilar SB4 in psoriatic patients

  • L. Pescitelli
  • L. Lazzeri
  • A. Di Cesare
  • L. Tripo
  • F. Ricceri
  • F. PrignanoEmail author
Short Research Report
  • 115 Downloads

Abstract

Background After the expiry of the patent of reference etanercept, several biosimilars have been developed, including SB4. Objective To study safety and efficacy of SB4 in psoriatic patients previously treated with etanercept and in the etanercept naive ones. Method Patients affected by moderate to severe psoriasis and/or psoriatic arthritis attending the Psoriasis Center of Florence University, treated with SB4 were enrolled in the study. Patients were divided in two cohorts. Cohort 1 included 32 patients who were switched from previous etanercept, cohort 2 included 12 patients who were naive to etanercept. Results Evaluation of the efficacy of SB4 in cohort 1 patients revealed rates of clinical remission (defined as both PASI and/or DAS28 increase < 10%) of 92% and 64% for psoriasis and psoriatic arthritis respectively. In cohort 2 at week 24 PASI 75 was observed in 75% of patients. Conclusion In our experience switching from originator to SB4 in psoriatic patients seems not to influence efficacy, especially cutaneous manifestations, over a median observational period of 24 weeks.

Keywords

Biologics Biosimilars Etanercept Psoriasis 

Notes

Funding

None.

Conflicts of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74(12):1379–410.CrossRefPubMedGoogle Scholar
  2. 2.
    Prinz JC, Puig L, Girolomoni G. Treatment of psoriasis with etanercept: the typical patient profile. J Eur Acad Dermatol Venereol. 2016;30(7):1092–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Weise M, Bielsky M-C, De Smet K, Ehmann F, Ekman N, Narayanan G, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29(8):690–3.CrossRefPubMedGoogle Scholar
  4. 4.
    Cho IH, Lee N, Song D, Jung SY, Bou-Assaf G, Sosic Z, et al. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. mAbs. 2016;8(6):1136–55.CrossRefPubMedGoogle Scholar
  5. 5.
    Burness CB, Duggan ST. Etanercept (SB4): a Review in Autoimmune Inflammatory Diseases. BioDrugs Clin Immunother Biopharm Gene Ther. 2016;30(4):371–8.Google Scholar
  6. 6.
    Emery P, Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):51–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Moots R, Azevedo V, Coindreau JL, Dörner T, Mahgoub E, Mysler E, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19(6):37.CrossRefPubMedGoogle Scholar
  8. 8.
    Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–19.CrossRefPubMedGoogle Scholar
  9. 9.
    Gisondi P, Bianchi L, Calzavara-Pinton P, Conti A, Chiricozzi A, Fimiani M, et al. Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Br J Dermatol. 2018.  https://doi.org/10.1111/bjd.17133 Google Scholar
  10. 10.
    Gerdes S, Thaçi D, Griffiths CEM, Arenberger P, Poetzl J, Wuerth G, Afonso M, Woehling H. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018;32(3):420–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Surgery and Translational Medicine, Section of DermatologyUniversity of FlorenceFlorenceItaly

Personalised recommendations